Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Sutent Gains First European Conditional Approval Recommendation

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm may renew sunitinib’s conditional marketing authorization after one year or transition to a full license.

You may also be interested in...



Pfizer’s Sutent Gains Conditional Approval In EU For GIST, Renal Cell Carcinoma

The company will submit Phase III data in August on sunitinib for RCC in order to gain full approval.

Pfizer’s Sutent Gains Conditional Approval In EU For GIST, Renal Cell Carcinoma

The company will submit Phase III data in August on sunitinib for RCC in order to gain full approval.

Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer

Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.

Related Content

Topics

UsernamePublicRestriction

Register

PS064290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel